Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 24Thoracic 12Dermatologic 9Breast 8Head & Neck 6Lymphoid 5Genitourinary 5Tumor-Agnostic 4Sarcoma 4Other solid neoplasm 4Gynecologic 4Plasma cell 2Other hematologic neoplasm 1Myeloid 1Endocrine 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × spartalizumab × Endocrine × Clear all
NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Completed
319 enrolled 41 charts
BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡